Black Diamond Therapeutics
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Find out what a historical investment in Black Diamond Therapeutics would be worth today using our BDTX stock calculator.
$99.18M
-
0.00%
0
$1.98
$1.75
$0.00
$6.75
$1.20
Ready to start your investing journey with Stake?
Open an accountBDTX FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in BDTX
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in BDTX
on Stake
Buy BDTX from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of BDTX from only US$10 with fractional shares
